views

GENinCode – ‘license approval’, how major an advance in the company's commercial programme?

GENinCode (GENI) has announced “a major advance in the company's commercial programme” – California state licensing approval and CLIA certification of its Irvine laboratory in California, enabling the provision of its products for the risk assessment of CVD to patients across 49 states in the United States. So what’s the detail and what of a current share price response towards 21p, up 170%?!